ArticleScientific reports2022
Robust antibacterial activity of functionalized carbon nanotube- levofloxacine conjugate based on in vitro and in vivo studies.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 55 citations in OpenAlex.
- Nanotechnology revolutionizing antimicrobial therapy for superbug infections.Discover nano · 2026Review
- Nanoparticle carriers in the treatment of intracellular bacterial infections: Current approaches and challenges.International journal of pharmaceutics: X · 2026Review
- Nanoparticle-Based Strategies to Combat Multidrug-Resistant Bacteria: Mechanisms, Applications, and Future Perspectives.MicrobiologyOpen · 2026Review
- Fabrication of stimuli-responsive chitosan-coated levofloxacin-incorporated zeolite imidazole nanoparticles for nursing care of wound healing.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nanomedicine in the Fight Against Multidrug-Resistant Infections: A Review on Emerging Strategies and Translational Prospects.International journal of nanomedicine · 2025Review
- Engineering innovations in medicine and biology: Revolutionizing patient care through mechanical solutions.Heliyon · 2024Review
- Levofloxacin loaded poly (ethylene oxide)-chitosan/quercetin loaded poly (D,L-lactide-co-glycolide) core-shell electrospun nanofibers for burn wound healing.Frontiers in bioengineering and biotechnology · 2024Article
- Characteristics and Key Features of Antimicrobial Materials and Associated Mechanisms for Diverse Applications.Molecules (Basel, Switzerland) · 2023Review
- Fighting bacterial pathogens with carbon nanotubes: focused review of recent progress.RSC advances · 2023Review
- Antibacterial Effect of Carbon Nanomaterials: Nanotubes, Carbon Nanofibers, Nanodiamonds, and Onion-like Carbon.Materials (Basel, Switzerland) · 2023Article
- Single -and Multi-Walled Carbon Nanotubes as Nanocarriers for the Delivery of 7-Hydroxyflavone.Pharmaceutics · 2022Article
- Combination Strategies of Different Antimicrobials: An Efficient and Alternative Tool for Pathogen Inactivation.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new nano-antibiotic was synthesized from the conjugation of multi-walled carbon nanotubes with levofloxacin (MWCNT-LVX) through covalent grafting of drug with surface-modified carbon nanotubes in order to achieve an effective, safe, fast-acting nano-drug with the minimal side effects. This study is the first report on the evaluation of in vitro cell viability and antibacterial activity of nano-antibiotic along in addition to the in vivo antibacterial activity in a burn wound model. The drug-loading and release profile at different pH levels was determined using an ultraviolet-visible spectrometer. MWCNT-LVX was synthesized by a simple, reproducible and cost-effective method for the first time and characterized using various techniques, such as scanning electron microscope, transmission electron microscopy, and Brunauer-Emmett-Teller analysis, and so forth. The noncytotoxic nano-antibiotic showed more satisfactory in vitro antibacterial activity against Staphylococcus aureus compared to Pseudomona aeruginosa. The novel synthetic nano-drug possessed high loading capacity and pH-sensitive release profile; resultantly, it exhibited very potent bactericidal activity in a mouse S. aureus wound infection model compared to LVX. Based on the results, the antibacterial properties of the drug enhanced after conjugating with surface-modified MWCNTs. The nano-antibiotic has great industrialization potential for the simple route of synthesis, no toxicity, proper drug loading and release, low effective dose, and strong activity against wound infections. In virtue of unique properties, MWCNTs can serve as a controlled release and delivery system for drugs. The easy penetration to biological membranes and barriers can also increase the drug delivery at lower doses compared to the main drug alone, which can lead to the reduction of its side effects. Hence, MWCNTs can be considered a promising nano-carrier of LVX in the treatment of skin infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.